

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application: **(AS ON AMENDED SHEET(S) ANNEXED TO IPRP)**

1. (original) Use of a first agent endowed with tumour tropism in combination with a second anticancer agent endowed with affinity for said first agent as active ingredients for the preparation of a medicament useful for the two-step perioperative therapy of solid tumours.
2. (original) Use according to claim 1, in which said first agent is administered during an intraoperative step via the locoregional route and said second agent is administered during a postoperative step via the systemic route.
3. (currently amended) Use according to ~~any of the foregoing claims~~ claim 1, in which said agent endowed with tumour tropism contains avidin.
4. (currently amended) Use according to ~~any of the foregoing claims~~ claim 1, in which said first agent is avidin and said second agent is a biotin compound bearing an anticancer agent.
5. (currently amended) Use according to ~~any of the foregoing claims~~ claim 1, in which said anticancer agent is selected from the group consisting of radioisotopes,

chemotherapeutic agents, toxins and anticancer cells.

6. (original) Use according to claim 5, in which said radioisotope is selected from the group consisting of Fe-52, Mn-52m, Co-55, Cu-64, Ga-67, Ga-68, Tc-99m, In-111, I-123, I-125, I-131, P-32, Sc-47, Cu-67, Y-90, Pd-109, Ag-111 I-131, Pm-149, Re-186, Re-188, At-211, Pb-212, Bi-212, and Lu-177.

7. (original) Use according to claim 6, in which said radioisotope is Y-90 or Lu-177.

8. (original) Use according to claim 4, in which the avidin and the biotin compound in said medicament are in separate containers.

9. (currently amended) Use according to ~~one of the foregoing claims~~ claim 1, in which said tumour is selected from the group consisting of breast, pancreas, lung, pleural, peritoneal, cervico-facial, brain and bladder tumours.

10. (currently amended) Use according to ~~one of claims 3-9~~ claim 3, in which said avidin is selected from the group consisting of avidin, streptavidin, their polymeric derivatives and their derivatives with polyethylene glycol..

11. (currently amended) Use according to ~~one of the foregoing claims~~ claim 1, in which said medicament is suitable for injectable administration.

12. (original) Use according to claim 11, in which the container of said avidin is in the form of a syringe suitable for successive administrations of precise volumes.

13. (original) Use according to claim 4, in which said avidin is contained in a separate container in a single dose.

14. (original) Use according to claim 4, in which the container of said avidin is suitable for administration in the form of a spray.

15. (original) Kit for two-step perioperative therapy, consisting of a set of separate containers, in which a first container contains an avidin compound, and a second container contains a biotin compound bearing an anticancer agent.

16. (original) Kit according to claim 15, in which the first container contains an avidinated antibody specific for antigens associated with a tumour or a mixture of antibodies, and the second container contains a biotin compound bearing an anticancer agent.

17. (original) Use of a first agent endowed with tumour tropism in combination with a second radiolabelled agent endowed with affinity for said first agent for the preparation of a diagnostic composition for the pretherapeutic biodistribution of the medicament according to claim 1.